Concurrent Care: Improving Access to End of Life Treatments

Authorized within §3140 of the Patient Protection and Affordable Care Act (ACA), the Medicare Hospice Concurrent Care Demonstration Program (Demonstration Program) may expand certain treatment options for Medicare patients seeking “end of life” care. Under current Medicare coverage policies, patients must choose between either curative treatment options or hospice care. However, through the Demonstration Program, HHS will evaluate the impact on patient care and quality of life, as well as the cost-effectiveness of reimbursing facilities for both curative treatment options and hospice care.¹

Medicare requires beneficiaries to forgo any curative treatment, i.e., treatment that is given with the intent of curing a particular condition, as a qualifier for providing coverage for hospice services, which has been “…the acknowledged gold standard for those at the end of life and their families.”² Medicare originally began covering hospice services in 1983, i.e., “…primarily because Congress saw it as cost-effective, and, generally speaking, foregoing expensive curative treatment in favor of less-intensive hospice services will reduce overall costs.”³ Restrictions limiting access between these two treatment options not only have the potential to create financial tensions for patients and their families when seeking end of life treatment,⁴ but may also “…cause[s] confusion likely resulting in healthcare professionals’ failure to recommend hospice as soon as they could.”⁵ Additionally, asking patients from certain cultures to choose “comfort” or palliative care to the exclusion of life-prolonging treatment may be in conflict with their cultural beliefs, thereby creating an access barrier to hospice care.⁶

The Demonstration Program is set to take place over a three year period, at no more than 15 hospice programs (located in both urban and rural areas) that will allow patients to receive hospice concurrently with other curative treatment(s) without incurring out of pocket expenses.⁷ Following the Demonstration Program, the Secretary of HHS must arrange for an independent evaluation to be submitted to Congress regarding the effect of providing concurrent care, specifically, whether the “…demonstration program has improved patient care, quality of life, and cost-effectiveness for Medicare beneficiaries participating in the demonstration program.”⁸

Proponents of the Demonstration Program advocate that eliminating the dichotomy between hospice and curative treatment will improve patient care and quality of life, while also lowering healthcare expenditures.⁹ A 2012 study published in the Journal of the American Geriatrics Society, and funded by the Alzheimer's Association and the National Institute on Aging, found that patients with advanced dementia in the last 90 days of life who received hospice care in addition to skilled nursing care required fewer aggressive treatments and were typically at lower risk of hospital death.¹⁰ The Alzheimer's Association study also found that without concurrent care treatment options, there were also certain financial incentives for unnecessary care to be provided to Medicare beneficiaries, due to providers attempting to offset typically lower Medicaid per diem rates by over treating Medicare beneficiaries in order to receive higher Medicare per diem rates.¹¹

While CMS has yet to set a start date for the Demonstration Program, some private payors, e.g., Aetna and UnitedHealthcare, have offered concurrent care options for several years.¹² In 2010, approximately 1.58 million patients in the U.S. received hospice care, of which 1.03 million died while under hospice care, which represented 41.9 percent of all U.S. deaths that year. Of those patients discharged from hospice care, a large percentage of these patients left a hospice program to pursue curative treatments. In 2010, 82.7 percent of hospice patients were 65 or older, and a majority of patients (38.9 percent) were over the age of 85.¹³ As the baby boomer population continues to age, the need for hospice care will likely increase, making quality and cost effective treatments a necessity. While pediatric patients account for less than one percent of hospice patients,¹⁴ a concurrent care amendment to the Medicaid program and the Children’s Health Insurance Program (CHIP), which was mandated under the ACA, also took effect in 2010, allowing for both hospice and curative reimbursement to be available for children seeking hospice care.¹⁵

---


Span, 2012.

Cerminara, 2013.

Ibid.


Ibid.

Cerminara, 2013.


Ibid, p. 2036.


Pub. L. 111-148, 124 STAT 293 (March 23, 2010); “Letter from CMS to State Health Officials Regarding Hospice Care for Children in Medicaid and CHIP” By Cindy Mann, Director of the Center for Medicaid, CHIP and Survey & Certification, to State Health Officials, SMD # 10-018, September 9, 2010.
Mr. Cimasi holds a Masters in Health Administration from the University of Maryland, as well as several professional designations: Accredited Senior Appraiser (ASA – American Society of Appraisers); Fellow Royal Intuition of Chartered Surveyors (FRICS – Royal Institute of Chartered Surveyors); Master Certified Business Appraiser (MCBA – Institute of Business Appraisers); Accredited Valuation Analyst (AVA – National Association of Certified Valuators and Analysts); and, Certified Merger & Acquisition Advisor (CM&AA – Alliance of Merger & Acquisition Advisors). He has served as an expert witness on cases in numerous courts, and has provided testimony before federal and state legislative committees. He is a nationally known speaker on healthcare industry topics, the author of several books, the latest of which include: “Accountable Care Organizations: Value Metrics and Capital Formation” [2013 - Taylor & Francis, a division of CRC Press], “The Adviser’s Guide to Healthcare” – Vols. I, II & III [2010 – AICPA], and “The U.S. Healthcare Certificate of Need Sourcebook” [2005 - Beard Books]. His most recent book, entitled “Healthcare Valuation: The Financial Appraisal of Enterprises, Assets, and Services” will be published by John Wiley & Sons in the Fall of 2013.

Mr. Cimasi is the author of numerous additional chapters in anthologies; books, and legal treatises; published articles in peer reviewed and industry trade journals; research papers and case studies; and, is often quoted by healthcare industry press. In 2006, Mr. Cimasi was honored with the prestigious “Shannon Pratt Award in Business Valuation” conferred by the Institute of Business Appraisers. Mr. Cimasi serves on the Editorial Board of the Business Appraisals Practice of the Institute of Business Appraisers, of which he is a member of the College of Fellows. In 2011, he was named a Fellow of the Royal Institution of Chartered Surveyors (RICS).

Todd A. Zigrang, MBA, MHA, ASA, FACHE, is the President of HEALTH CAPITAL CONSULTANTS (HCC), where he focuses on the areas valuation and financial analysis for hospitals and other healthcare enterprises. Mr. Zigrang has significant physician integration and financial analysis experience, and has participated in the development of a physician-owned multi-specialty MSO and networks involving a wide range of specialties; physician-owned hospitals, as well as several limited liability companies for the purpose of acquiring acute care and specialty hospitals, ASCs and other ancillary facilities; participated in the evaluation and negotiation of managed care contracts, performed and assisted in the valuation of various healthcare entities and related litigation support engagements; created pro-forma financials; written business plans; conducted a range of industry research; completed due diligence practice analysis; oversee the selection process for vendors, contractors, and architects; and, worked on the arrangement of financing.

Mr. Zigrang holds a Master of Science in Health Administration and a Masters in Business Administration from the University of Missouri at Columbia. He is a Fellow of the American College of Healthcare Executives, and serves as President of the St. Louis Chapter of the American Society of Appraisers (ASA). He has co-authored “Research and Financial Benchmarking in the Healthcare Industry” (STP Financial Management) and “Healthcare Industry Research and its Application in Financial Consulting” (Aspen Publishers). He has additionally taught before the Institute of Business Appraisers and CPA Leadership Institute, and has presented healthcare industry valuation related research papers before the Healthcare Financial Management Association; the National CPA Health Care Adviser’s Association; Association for Corporate Growth; Infocast Executive Education Series; the St. Louis Business Valuation Roundtable; and, Physician Hospitals of America.

Anne P. Sharamitro, Esq., is the Executive Vice President & General Counsel of HEALTH CAPITAL CONSULTANTS (HCC), where she focuses on the areas of Certificate of Need (CON); regulatory compliance, managed care, and antitrust consulting. Ms. Sharamitro is a member of the Missouri Bar and holds a J.D. and Health Law Certificate from Saint Louis University School of Law, where she served as an editor for the Journal of Health Law, published by the American Health Lawyers Association. Ms. Sharamitro has presented healthcare industry related research papers before Physician Hospitals of America and the National Association of Certified Valuation Analysts and co-authored chapters in “Healthcare Organizations: Financial Management Strategies,” published in 2008.